Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 3/2017

01-03-2017 | Systemic Lupus Erythematosus (G Tsokos, Section Editor)

ApoL1 and the Immune Response of Patients with Systemic Lupus Erythematosus

Authors: Ashira D. Blazer, Robert M. Clancy

Published in: Current Rheumatology Reports | Issue 3/2017

Login to get access

Abstract

Purpose of Review

Systemic lupus erythematosus (SLE) confers up to a 50-fold increased risk of cardiovascular disease (CVD), and African Americans with SLE experience accelerated damage accrual and doubled cardiovascular risk when compared to their European American counterparts.

Recent Findings

Genome-wide association studies have identified a substantial signal at 22q13, now assigned to variation at apolipoprotein L1 (APOL1), which has associated with progressive nondiabetic nephropathy, cardiovascular disease, and many immune-associated renal diseases, including lupus nephritis.

Summary

We contend that alterations in crucial APOL1 intracellular pathways may underpin associated disease states based on structure-functional differences between variant and ancestral forms. While ancestral APOL1 may be a key driver of autophagy, nonconserved primary structure changes result in a toxic gain of function with attenuation of autophagy and an unsupervised pore-forming feature. Thus, the divergent intracellular biological pathways of ancestral and variant APOL1 may explain a worsened prognosis as demonstrated in SLE.
Literature
1.
Page NM, Butlin DJ, Lomthaisong K, Lowry PJ. The human apolipoprotein L gene cluster: identification, classification, and sites of distribution. Genomics. 2001;74:71–8.CrossRefPubMed
2.
Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, Nolan DP, Lins L, Van Den Abbeele J, et al. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature. 2003;422:83–7.CrossRefPubMed
3.
4.
Grams ME, Rebholz CM, Chen Y, Rawlings AM, Estrella MM, Selvin E, et al. Race, APOL1 risk, and eGFR decline in the general population. J Am Soc Nephrol. 2016;27:2842–50.PubMed
5.
Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med. 2013;369:2183–96.CrossRefPubMedPubMedCentral
6.
Langefeld CD, Divers J, Pajewski NM, Hawfield AT, Reboussin DM, Bild DE, et al. Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial. Kidney Int. 2015;87:169–75.CrossRefPubMed
7.
Mukamal KJ, Tremaglio J, Friedman DJ, Ix JH, Kuller LH, Tracy RP, et al. APOL1 genotype, kidney and cardiovascular disease, and death in older adults. Arterioscler Thromb Vasc Biol. 2016;36:398–403.CrossRefPubMed
8.
Ito K, Bick AG, Flannick J, Friedman DJ, Genovese G, Parfenov MG, et al. Increased burden of cardiovascular disease in carriers of APOL1 genetic variants. Circ Res. 2014;114:845–50.CrossRefPubMed
9.
Thomson R, Genovese G, Canon C, Kovacsics D, Higgins Matthew K, Carrington M, et al. Evolution of the primate trypanolytic factor APOL1. Proc Natl Acad Sci U S A. 2014;111(20):E2130–9. 966762.CrossRefPubMedPubMedCentral
10.
Monajemi H, Fontijn RD, Pannekoek H, Horrevoets AJ. The apolipoprotein L gene cluster has emerged recently in evolution and is expressed in human vascular tissue. Genomics. 2002;79:539–46.CrossRefPubMed
11.
12.
•• Wan G, Zhaorigetu S, Liu Z, Kaini R, Jiang Z, Hu CA. Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. J Biol Chem. 2008;283:21540–9. BH3 domain of ApoL1 is essential for autophagy.CrossRefPubMedPubMedCentral
13.
•• Sharma AK, Friedman DJ, Pollak MR, Alper SL. Structural characterization of the C-terminal coiled-coil domains of wild-type and kidney disease-associated mutants of apolipoprotein L1. FEBS J. 2016;283:1846–62. Biophysical data and molecular dynamic simulation of ancestral, variant forms of ApoL1.CrossRefPubMed
14.
Rosset S, Tzur S, Behar DM, Wasser WG, Skorecki K. The population genetics of chronic kidney disease: insights from the MYH9-APOL1 locus. Nat Rev Nephrol. 2011;7:313–26.CrossRefPubMed
15.
• Freedman BI, Langefeld CD, Andringa KK, Croker JA, Williams AH, Garner NE, et al. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol. 2014;66:390–6. Association of ApoL1 alleles and severe lupus nephritis with end-stage renal disease.CrossRefPubMedPubMedCentral
16.
• Lipkowitz MS, Freedman BI, Langefeld CD, Comeau ME, Bowden DW, Kao WH, et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int. 2013;83:114–20. Association of ApoL1 alleles and CKD with essential hypertension in non-diabetic AASK subjects.CrossRefPubMed
17.
Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011;22:2129–37.CrossRefPubMedPubMedCentral
18.
Kasembeli AN, Duarte R, Ramsay M, Mosiane P, Dickens C, Dix-Peek T, et al. APOL1 risk variants are strongly associated with HIV-associated nephropathy in Black South Africans. J Am Soc Nephrol. 2015;26:2882–90.CrossRefPubMedPubMedCentral
19.
Blazer A, Clancy RM, Belmont MH, Izmirly PM, Markham A, Buyon JB. Apolipoprotein L1 risk variants associate with prevalent cardiovascular disease in African American systemic lupus erythematosus patients. Arthritis Rheumatol. 2016.
20.
Duchateau PN, Pullinger CR, Cho MH, Eng C, Kane JP. Apolipoprotein L gene family: tissue-specific expression, splicing, promoter regions; discovery of a new gene. J Lipid Res. 2001;42:620–30.PubMed
21.
Limou S, Dummer PD, Nelson GW, Kopp JB, Winkler CA. APOL1 toxin, innate immunity, and kidney injury. Kidney Int. 2015.
22.
•• Nichols B, Jog P, Lee JH, Blackler D, Wilmot M, D’Agati V, et al. Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. Kidney Int. 2015;87:332–42. Kidney disease in the context of ApoL1 alleles and environment due to bacteria and viruses.CrossRefPubMed
23.
Blazer A, Buyon JB, Clancy R. Heritable Endotheliopathy and ApolipoproteinL1 Risk Traits in SLE. Arthritis Rheumatol. 2015;67.
24.
McNicholas BA, Nelson PJ. Immunity unmasks APOL1 in collapsing glomerulopathy.
25.
26.
Lan X, Jhaveri A, Cheng K, Wen H, Saleem MA, Mathieson PW, et al. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability. Am J Physiol Renal physiol. 2014;307:F326–36.CrossRefPubMedPubMedCentral
27.
Cheng D, Weckerle A, Yu Y, Ma L, Zhu X, Murea M, et al. Biogenesis and cytotoxicity of APOL1 renal risk variant proteins in hepatocytes and hepatoma cells. J Lipid Res. 2015;56:1583–93.CrossRefPubMedPubMedCentral
28.
Ma L, Shelness GS, Snipes JA, Murea M, Antinozzi PA, Cheng D, et al. Localization of APOL1 Protein and mRNA in the Human Kidney: Nondiseased Tissue, Primary Cells, and Immortalized Cell Lines. Journal of the American Society of Nephrology: JASN. 2014
29.
Heneghan JF, Vandorpe DH, Shmukler BE, Giovinazzo JA, Raper J, Friedman DJ, et al. BH3 domain-independent apolipoprotein L1 toxicity rescued by BCL2 prosurvival proteins. Am J Physiol Cell Physiol. 2015;309:C332–47.CrossRefPubMedPubMedCentral
30.
• Olabisi OA, Zhang JY, VerPlank L, Zahler N, 3rd DiBartolo S, Heneghan JF, et al. APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases. Proc Natl Acad Sci U S A. 2016;113:830–7. The intracellular properties of Ancestral and variant alleles diverge from one another.CrossRefPubMed
31.
Thomson R, Finkelstein A. Human trypanolytic factor APOL1 forms pH-gated cation-selective channels in planar lipid bilayers: relevance to trypanosome lysis. Proc Natl Acad Sci U S A. 2015;112:2894–9.CrossRefPubMedPubMedCentral
32.
Pozzan T, Lew DP, Wollheim CB, Tsien RY. Is cytosolic ionized calcium regulating neutrophil activation? Science. 1983;221:1413–5.CrossRefPubMed
33.
Wang Y, Li M, Stadler S, Correll S, Li P, Wang D, et al. Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J Cell Biol. 2009;184:205–13.CrossRefPubMedPubMedCentral
34.
35.
Akl I, Lelubre C, Uzureau P, Piagnerelli M, Biston P, Rousseau A, et al. Apolipoprotein L Expression Correlates with Neutrophil Cell Death in Critically Ill Patients. Shock. 2016
36.
37.
Hosoi E, Nishizaki C, Gallagher KL, Wyre HW, Matsuo Y, Sei Y. Expression of the ryanodine receptor isoforms in immune cells. J Immunol. 2001;167:4887–94.CrossRefPubMed
38.
Cheong E, Tumbev V, Abramson J, Salama G, Stoyanovsky DA. Nitroxyl triggers Ca2+ release from skeletal and cardiac sarcoplasmic reticulum by oxidizing ryanodine receptors. Cell Calcium. 2005;37:87–96.CrossRefPubMed
39.
Menard LC, Habte S, Gonsiorek W, Lee D, Banas D, Holloway DA, et al. B cells from African American lupus patients exhibit an activated phenotype. JCI Insight. 2016;1, e87310.CrossRefPubMedPubMedCentral
40.
41.
Singh KK, Lovren F, Pan Y, Quan A, Ramadan A, Matkar PN, et al. The essential autophagy gene ATG7 modulates organ fibrosis via regulation of endothelial-to- mesenchymal transition. J Biol Chem. 2015;290:2547–59.CrossRefPubMed
42.
Maiuri MC, Le Toumelin G, Criollo A, Rain JC, Gautier F, Juin P, et al. Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J. 2007;26:2527–39.CrossRefPubMedPubMedCentral
43.
Martinez J, Cunha LD, Park S, Yang M, Lu Q, Orchard R, et al. Noncanonical autophagy inhibits the autoinflammatory, lupus-like response to dying cells. Nature. 2016;533:115–9.CrossRefPubMedPubMedCentral
44.
Limou S, Nelson GW, Kopp JB, Winkler CA. APOL1 kidney risk alleles: population genetics and disease associations. Adv Chronic Kidney Dis. 2014;21:426–33.CrossRefPubMedPubMedCentral
45.
Liu X, Qin H, Xu J. The role of autophagy in the pathogenesis of systemic lupus erythematosus. Int Immunopharmacol. 2016;40:351–61.CrossRefPubMed
46.
Harris J, Hartman M, Roche C, Zeng SG, O’Shea A, Sharp FA, et al. Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation. J Biol Chem. 2011;286:9587–97.CrossRefPubMedPubMedCentral
47.
Konno H, Konno K, Barber GN. Cyclic dinucleotides trigger ULK1 (ATG1) phosphorylation of STING to prevent sustained innate immune signaling. Cell. 2013;155:688–98.CrossRefPubMed
48.
Peral de Castro C, Jones SA, Ni Cheallaigh C, Hearnden CA, Williams L, Winter J, et al. Autophagy regulates IL-23 secretion and innate T cell responses through effects on IL-1 secretion. J Immunol. 2012;189:4144–53.CrossRefPubMed
49.
50.
Nedjic J, Aichinger M, Emmerich J, Mizushima N, Klein L. Autophagy in thymic epithelium shapes the T-cell repertoire and is essential for tolerance. Nature. 2008;455:396–400.CrossRefPubMed
51.
Jia W, He YW. Temporal regulation of intracellular organelle homeostasis in T lymphocytes by autophagy. J Immunol. 2011;186:5313–22.
52.
Schmid D, Pypaert M, Munz C. Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes. Immunity. 2007;26:79–92.
Metadata
Title
ApoL1 and the Immune Response of Patients with Systemic Lupus Erythematosus
Authors
Ashira D. Blazer
Robert M. Clancy
Publication date
01-03-2017
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 3/2017
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-017-0637-9

Other articles of this Issue 3/2017

Current Rheumatology Reports 3/2017 Go to the issue

Rheumatoid Arthritis (L Moreland, Section Editor)

The Multifunctional Role of the Chemokine System in Arthritogenic Processes

Systemic Lupus Erythematosus (G Tsokos, Section Editor)

Novel Treatments in Lupus

Surgery and Perioperative Care (S Goodman, Section Editor)

Can Rheumatologists Predict Eventual Need for Orthopaedic Intervention in Patients with Rheumatoid Arthritis? Results of a Systematic Review and Analysis of Two UK Inception Cohorts

Spondyloarthritis (M Khan, Section Editor)

Structural Disease Progression in Axial Spondyloarthritis: Still a Cause for Concern?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits